靶向嗜酸性粒细胞的生物疗法：现状与未来前景。
Biologic therapies targeting eosinophils: current status and future prospects.
作者信息
Legrand Fanny, Klion Amy D
机构信息
Human Eosinophil Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda.
Human Eosinophil Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda.
出版信息
J Allergy Clin Immunol Pract. 2015 Mar-Apr;3(2):167-74. doi: 10.1016/j.jaip.2015.01.013.
Abstract
The recent explosion in the number of biologic therapies in clinical development for the treatment of eosinophilic disorders is unprecedented. As these agents become available for clinical use, the selection of the most appropriate agent for a given patient will become increasingly complicated. The aims of this review were 2-fold: (1) to present the lessons learned from clinical trials using the first generation of eosinophil-targeted biologics (anti-IL-5 antibodies) and (2) to discuss the advantages and potential limitations of currently available and novel targeted therapies to treat eosinophilic disorders.
摘要
目前用于治疗嗜酸性粒细胞疾病的生物疗法在临床开发中的数量激增，这是前所未有的。随着这些药物可供临床使用，为特定患者选择最合适的药物将变得越来越复杂。本综述的目的有两个：（1）介绍使用第一代嗜酸性粒细胞靶向生物制剂（抗IL-5抗体）的临床试验所吸取的经验教训；（2）讨论目前可用的和新型靶向疗法治疗嗜酸性粒细胞疾病的优势和潜在局限性。
相似文献
1
Biologic therapies targeting eosinophils: current status and future prospects.靶向嗜酸性粒细胞的生物疗法：现状与未来前景。
J Allergy Clin Immunol Pract. 2015 Mar-Apr;3(2):167-74. doi: 10.1016/j.jaip.2015.01.013.
2
Benralizumab for the treatment of asthma.贝那利珠单抗用于治疗哮喘。
Expert Rev Clin Immunol. 2017 May;13(5):405-413. doi: 10.1080/1744666X.2017.1316194. Epub 2017 Apr 19.
3
Anti-IL5 therapies for asthma.用于哮喘的抗白细胞介素-5疗法。
Cochrane Database Syst Rev. 2017 Sep 21;9(9):CD010834. doi: 10.1002/14651858.CD010834.pub3.
4
Immunological and hematological effects of IL-5(Rα)-targeted therapy: An overview.IL-5（Rα）靶向治疗的免疫和血液学效应：概述。
Allergy. 2018 Oct;73(10):1979-1988. doi: 10.1111/all.13451. Epub 2018 Oct 8.
5
Biological therapies for eosinophilic asthma.用于嗜酸性粒细胞性哮喘的生物疗法。
Expert Opin Biol Ther. 2018 Jul;18(7):747-754. doi: 10.1080/14712598.2018.1492540. Epub 2018 Jul 4.
6
Anti-IL-5 therapies for asthma.哮喘的抗 IL-5 治疗。
Cochrane Database Syst Rev. 2022 Jul 12;7(7):CD010834. doi: 10.1002/14651858.CD010834.pub4.
7
Eosinophil Development, Disease Involvement, and Therapeutic Suppression.嗜酸性粒细胞的发育、疾病参与和治疗抑制。
Adv Immunol. 2018;138:1-34. doi: 10.1016/bs.ai.2018.03.001. Epub 2018 Apr 22.
8
The roles of IL-5 and anti-IL-5 treatment in eosinophilic diseases: Asthma, eosinophilic granulomatosis with polyangiitis, and eosinophilic chronic rhinosinusitis.IL-5 及其拮抗剂在嗜酸性粒细胞疾病中的作用：哮喘、嗜酸性肉芽肿伴多血管炎和嗜酸性慢性鼻-鼻窦炎。
Allergol Int. 2020 Apr;69(2):178-186. doi: 10.1016/j.alit.2020.02.002. Epub 2020 Mar 2.
9
Reslizumab Compared with Benralizumab in Patients with Eosinophilic Asthma: A Systematic Literature Review and Network Meta-Analysis.雷索芦单抗对比贝那利珠单抗治疗嗜酸性粒细胞性哮喘患者的疗效：系统文献回顾和网络荟萃分析。
J Allergy Clin Immunol Pract. 2019 Jan;7(1):122-130.e1. doi: 10.1016/j.jaip.2018.08.036. Epub 2018 Sep 11.
10
Biologics for the Treatment of Allergic Conditions: Eosinophil Disorders.用于治疗过敏病症的生物制剂：嗜酸性粒细胞疾病。
Immunol Allergy Clin North Am. 2020 Nov;40(4):649-665. doi: 10.1016/j.iac.2020.07.001. Epub 2020 Sep 12.
引用本文的文献
1
Eosinophils Play a Surprising Leading Role in Recurrent Urticaria in Horses.嗜酸性粒细胞在马的复发性荨麻疹中发挥着惊人的主导作用。
Vaccines (Basel). 2024 May 21;12(6):562. doi: 10.3390/vaccines12060562.
2
Eosinophilic Myocarditis: From Bench to Bedside.嗜酸性粒细胞性心肌炎：从实验台到病床边
Biomedicines. 2024 Mar 14;12(3):656. doi: 10.3390/biomedicines12030656.
3
Real-World Safety and Effectiveness of Benralizumab in Japanese Patients with Severe Asthma: A Multicenter Prospective Observational Study.贝那利珠单抗在日本重度哮喘患者中的真实世界安全性和有效性：一项多中心前瞻性观察研究。
J Asthma Allergy. 2024 Jan 20;17:45-60. doi: 10.2147/JAA.S432695. eCollection 2024.
4
Eosinophilic-Associated Disease Overlap: What Do We Know About It?嗜酸性粒细胞相关疾病重叠：我们对此了解多少？
Allergy Asthma Immunol Res. 2023 Sep;15(5):539-542. doi: 10.4168/aair.2023.15.5.539.
5
A diagnostic model for predicting type 2 nasal polyps using biomarkers in nasal secretion.利用鼻分泌物中的生物标志物预测 2 型鼻息肉的诊断模型。
Front Immunol. 2022 Dec 21;13:1054201. doi: 10.3389/fimmu.2022.1054201. eCollection 2022.
6
Recent advances in understanding the role of eosinophils.嗜酸性粒细胞作用认识的最新进展。
Fac Rev. 2022 Sep 27;11:26. doi: 10.12703/r/11-26. eCollection 2022.
7
Investigational Treatments in Phase I and II Clinical Trials: A Systematic Review in Asthma.I期和II期临床试验中的研究性治疗：哮喘的系统评价
Biomedicines. 2022 Sep 19;10(9):2330. doi: 10.3390/biomedicines10092330.
8
Recent advances of eosinophils and its correlated diseases.近年来嗜酸性粒细胞及其相关疾病的研究进展。
Front Public Health. 2022 Jul 25;10:954721. doi: 10.3389/fpubh.2022.954721. eCollection 2022.
9
Therapeutic Strategies of Biologics in Chronic Rhinosinusitis: Current Options and Future Targets.生物制剂治疗慢性鼻-鼻窦炎的策略：现有选择与未来靶点。
Int J Mol Sci. 2022 May 15;23(10):5523. doi: 10.3390/ijms23105523.
10
Modulation of surface CD11c expression tracks plasticity in murine intestinal tissue eosinophils.表面 CD11c 表达的调节跟踪了鼠类肠道组织嗜酸性粒细胞的可塑性。
J Leukoc Biol. 2022 May;111(5):943-952. doi: 10.1002/JLB.3HI0821-432RR. Epub 2022 Feb 9.
本文引用的文献
1
A randomized trial of benralizumab, an antiinterleukin 5 receptor α monoclonal antibody, after acute asthma.一项关于抗白细胞介素5受体α单克隆抗体贝那利珠单抗在急性哮喘后应用的随机试验。
Am J Emerg Med. 2015 Jan;33(1):14-20. doi: 10.1016/j.ajem.2014.09.036. Epub 2014 Oct 5.
2
Developing and emerging clinical asthma phenotypes.发展中与新兴的临床哮喘表型。
J Allergy Clin Immunol Pract. 2014 Nov-Dec;2(6):671-80; quiz 681. doi: 10.1016/j.jaip.2014.09.007. Epub 2014 Oct 5.
3
Novel targeted therapies for eosinophil-associated diseases and allergy.嗜酸性粒细胞相关疾病和过敏的新型靶向疗法。
Annu Rev Pharmacol Toxicol. 2015;55:633-56. doi: 10.1146/annurev-pharmtox-010814-124407. Epub 2014 Oct 17.
4
Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study.贝那利珠单抗，一种抗白细胞介素 5 受体 α 单克隆抗体，与安慰剂相比用于治疗未控制的嗜酸性粒细胞性哮喘：一项 2b 期随机剂量范围研究。
Lancet Respir Med. 2014 Nov;2(11):879-890. doi: 10.1016/S2213-2600(14)70201-2. Epub 2014 Oct 8.
5
IL-5 triggers a cooperative cytokine network that promotes eosinophil precursor maturation.白细胞介素-5触发一个促进嗜酸性粒细胞前体成熟的协同细胞因子网络。
J Immunol. 2014 Oct 15;193(8):4043-52. doi: 10.4049/jimmunol.1400732. Epub 2014 Sep 17.
6
Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis.静脉注射抗 IL-13 mAb QAX576 治疗嗜酸性食管炎。
J Allergy Clin Immunol. 2015 Feb;135(2):500-7. doi: 10.1016/j.jaci.2014.07.049. Epub 2014 Sep 13.
7
Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study.贝那鲁肽治疗慢性阻塞性肺疾病和痰嗜酸性粒细胞增多症：一项随机、双盲、安慰剂对照、2a 期研究。
Lancet Respir Med. 2014 Nov;2(11):891-901. doi: 10.1016/S2213-2600(14)70187-0. Epub 2014 Sep 7.
8
Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.美泊利珠单抗在嗜酸性粒细胞性哮喘中的口服糖皮质激素节省作用。
N Engl J Med. 2014 Sep 25;371(13):1189-97. doi: 10.1056/NEJMoa1403291. Epub 2014 Sep 8.
9
Mepolizumab treatment in patients with severe eosinophilic asthma.美泊利珠单抗治疗严重嗜酸性粒细胞性哮喘患者。
N Engl J Med. 2014 Sep 25;371(13):1198-207. doi: 10.1056/NEJMoa1403290. Epub 2014 Sep 8.
10
Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.度普利尤单抗治疗中重度特应性皮炎成人患者。
N Engl J Med. 2014 Jul 10;371(2):130-9. doi: 10.1056/NEJMoa1314768.
Zotero 插件